Agios Pharmaceuticals, Inc.

agios.com

What Do They Do?

Develops and sells medicines for patients with rare blood disorders, including anemia, thalassemia and PK deficiency.

How Do They Make Money?

Agios sells PYRUKYND to specialty distributors and specialty pharmacy providers in the United States, and to Avanzanite and NewBridge outside the United States. A sale counts when the customer receives the medicine, typically upon delivery.

FY2025 revenue

Who Are Their Customers?

In the United States, specialty distributors and specialty pharmacy providers buy PYRUKYND; outside the United States, Agios sells to Avanzanite and NewBridge. Those customers resell it to pharmacies or dispense it directly to patients.

Customers above 10% of revenue, FY2025

of revenue from one customer

FY2023: 96% from one customer

Do Revenues Turn Into Profits?

No. It lost $412.8M in FY2025.

Operating income, FY2025

−874% of revenue

▲ +11% (Loss) vs FY2024 (−$425.7M, −1166%)

Net income, FY2025

−764% of revenue

▼ Now a loss vs FY2024 ($673.7M, 1846%)

Free cash flow, FY2025

−698% of revenue

▼ −4% (Loss) vs FY2024 (−$391.5M, −1073%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +259%; vs $12.5M in Q2 FY2025
Net income: ▼ −10% (Loss); vs −$112M in Q2 FY2025

Jul 30, 2026 Agios licenses cevidoplenib for immune thrombocytopenia Agios agreed with Oscotec to license exclusive global rights to the oral drug candidate.

Thalassemia treatment Mitapivat moved from being approved for PK deficiency, while in trials for thalassemia, to approved products for thalassemia as well as PK deficiency.

Broader pipeline The earlier report described PK activators and a PAH stabilizer; the latest also describes a licensed RNA-based candidate for polycythemia vera.

Who Do They Compete With?

Competes with BioMarin, Bristol-Myers Squibb, Cellarity, CRISPR Therapeutics, DISC Medicine, Emmaus Life Sciences, Fulcrum Therapeutics, Genetix, Geron, Halia, Incyte, Ionis Pharmaceuticals, Italfarmaco, Maze Therapeutics, Merck, NGGT, Novartis, Novo, Otsuka, and Pfizer

Comments